A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Empowering Netflix Series ‘Skin Decision: Before and After’ Scores 2021 Emmy Nomination for Its Debut Season

On the heels of its debut season, Netflix’s original medical/lifestyle reality show Skin Decision: Before and After has received a 2021 Emmy nomination for “Outstanding Lifestyle Series.” The series takes a unique approach to its genre, as it seeks to bring healing, confidence, and self-empowerment to people who have endured traumatic and life-altering experiences.

Featuring board-certified plastic surgeon Dr. Sheila Nazarian, Skin Decision goes beyond superficial appearances and highlights the beauty within each patient while sharing intimate and emotional stories of real-life people who have suffered everything from confidence-crushing relationships to near-fatal car crashes.

When this project came up, I was so excited to get involved. I really wanted to make a new kind of plastic surgery show. Not a circus. Not demeaning to patients,” Nazarian says. “With this show, we really elevated plastic surgery and aesthetic treatments and showed the very real reasons why people get work done. Also, we showed that looking better can make people feel better and do better.”

Though future plans for the show have yet to be disclosed, Dr. Nazarian has many other accomplishments in sight. In addition to running her private practice in Beverly Hills, she will be expanding into Lake Tahoe soon with Spa26& Nazarian Plastic Surgery. Her non-profit, Nazarian Institute and ThinkBIG!, is growing to include surgical education and techniques for other board-certified plastic surgeons. Her ecommerce site The Skin Spot is ready for its re-launch with the new Skin Quiz, curated medical-grade skincare product offerings, Loyalty Points, and a sampling program. She also intends to continue her activism work to end racism against Jews all around the world.

The full series of Skin Decision: Before and After is available on Netflix. The 2021 Emmy Awards will be broadcast on Sept. 19, 2021, on CBS.



Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy